FoldRx is a leader in the discovery and development of first in class disease modifying drug therapies for diseases of protein misfolding and amyloidosis.

Misfolded protein is an emerging concept that has recently begun to gain momentum in the scientific community as the underlying cause of many chronic and late onset diseases such as Parkinson's, Alzheimer's, Huntington's disease, Cardiomyopathy, and Polyneuropathy. FoldRx has broad intellectual property coverage of its screening tools and areas of focus. Some of the world's leading experts in protein misfolding and amyloid are associated with the company.




Home | About Us | Science | News & Publications | Careers | Contact
© 2003-2007. FoldRx Pharmaceuticals, Inc. All Rights Reserved.